Skip to content

Plicamycin

ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Also known as: aureolic acid, mithracin, mithramycin, Mithramycin A, mithramycinum, mitramycin, plicatomycin

OfmFDA approvedATC L01DC02

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Plicamycin is an ofm drug catalogued in DrugCentral. It was first approved by the FDA in 1970. Recorded indications include Malignant tumor of testis.

  • Approval status: ofm (first approved 1970 by the FDA).
  • Indications: Malignant tumor of testis.
  • ATC code: L01DC02 (Other cytotoxic antibiotics).
  • Molecular formula: C52H76O24; molecular weight 1085.16 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

  • Malignant tumor of testis

Regulatory approvals (1)

DateAgencyMarketed asApplicantOrphan
1970-05-05FDA——

ATC classification

ATC codeTherapeutic hierarchy
L01DC02ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES › Other cytotoxic antibiotics

Chemical structure

Molecular formulaC52H76O24
Molecular weight1085.16 g/mol
CAS number18378-89-7
InChIKeyCFCUWKMKBJTWLW-BKHRDMLASA-N
PubChem CID163659
CO[C@@H]([C@@H]1CC2=CC3=CC(O[C@H]4C[C@@H](O[C@H]5C[C@@H](O)[C@H](O)[C@@H](C)O5)[C@H](O)[C@@H](C)O4)=C(C)C(O)=C3C(O)=C2C(=O)[C@H]1O[C@H]1C[C@@H](O[C@H]2C[C@@H](O[C@H]3C[C@](C)(O)[C@H](O)[C@@H](C)O3)[C@@H](O)[C@@H](C)O2)[C@H](O)[C@@H](C)O1)C(=O)[C@@H](O)[C@@H](C)O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Plicamycin used for?

DrugCentral lists the following indications for Plicamycin: Malignant tumor of testis.

When was Plicamycin first approved?

Plicamycin was first approved by the FDA in 1970.

What is the chemical formula of Plicamycin?

Plicamycin has the molecular formula C52H76O24 and a molecular weight of 1085.16 g/mol.

Browse: all drugs starting with P · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

StatusOFM
First approval1970-05-05
AgencyFDA
Targets0
Indications1
FormulaC52H76O24
DrugCentral ID2223
Interactive profile